Cumberland Pharmaceuticals Inc (CPIX)
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-09-04
$6.79+0.59%
Close 2026-09-04 · 1-day change
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-09-04
QuarterlyIQ Insights · CPIX
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -45.6% |
| Our one-year growth estimate | diamond |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| 16.4% |
Growth built into the price is above our model estimate.
The price assumes 62.0 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 24 industry peers · Company calendar date is not available
CPIX — M&A activity — Termination of a Material Definitive Agreement
Dated 2026-07-01
Termination of a Material Definitive Agreement. On June 29, 2026, in connection with the closing of the Transaction, Cumberland terminated and repaid in full all outstanding obligations (approximately $5.3 million) due under that certain Revolving Credit Loan Agreement, dated as of September 5, 2023, by and between Pinnacle Bank and the Company (as amended, the “ Loan Agreement ”). In connection with the termination and repayment in full of all outstanding obligations under the Loan Agreement…
Why it matters: Progress in the DMD trial is crucial for future FDA approval and market potential. Positive updates could enhance the pipeline's value.
Supportive ifCumberland shares good updates or talks with the FDA about the DMD trial results.
Worry ifCumberland reports setbacks or negative feedback from the FDA regarding the DMD trial.
Why it matters: These results will show if ifetroban works for Systemic Sclerosis. Good results could help the stock and support the pipeline.
Supportive ifTop-line results from the Phase II study are announced.
Worry ifResults show ifetroban does not work or if there are safety issues.
Why it matters: If integration works, it will show Cumberland can focus on rare diseases. It will also improve efficiency.
Supportive ifCumberland says it has finished integration steps. They see benefits from working together.
Worry ifIntegration may have delays or problems that slow down progress.
Why it matters: The special dividend could change how investors feel and affect stock value.
Supportive ifCPIX share price goes up after the $1.50 special dividend is paid.
Worry ifCPIX share price declines or remains stagnant after the dividend payment.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$242 on $10,000 · ±2.4% | How much price usually moves either way. |
| Bad day | $803 loss on $10,000 · 8.0% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $4,829 loss on $10,000 · 48.3% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Solving legal issues can lower risk and help finances. It affects investor trust.
Watch forA positive outcome or settlement in the ongoing legal case.
Also watch forNew legal cases are filed or there are bad news in current cases.
Why it matters: Top-line results from this study will indicate if the drug is effective for this serious condition. Positive results could enhance the drug's market potential.
Supportive ifThe Phase II study results are out. They show ifetroban works well.
Worry ifResults show ifetroban does not work well. This raises doubts about its future.
Why it matters: Share buybacks could show management's trust in the company and help the stock price.
Supportive ifCumberland completes share buybacks as part of its $5 million program.
Worry ifNo share buybacks happen or management delays the buyback plan.